Neo-adjuvant hormonotherapy does not facilitate radical prostatectomy.
Sixty-eight patients who underwent radical prostatectomy without or after neo-adjuvant hormonotherapy for B2 or C stage prostate cancer were evaluated as concerned to the ease of the surgical procedure. Although it is difficult to assess this parameter, we experienced more difficulties and blood loss was higher in patients who had preoperative hormonal deprivation. Ongoing randomized trials could demonstrate an oncological benefit of neo-adjuvant hormonotherapy before radical prostatectomy. This eventual benefit will have to be balanced against an increased surgical difficulty.
Van Poppel
H
H
University Hospital, Katholieke Universiteit Leuven, Belgium.
Ameye
F
F
Oyen
R
R
Van De Voorde
W
W
Baert
L
L
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D016063:Blood Loss, Surgical; D017024:Chemotherapy, Adjuvant; D003534:Cyproterone / Q000008:administration & dosage; D004961:Estramustine / Q000008:administration & dosage; D005485:Flutamide / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery
D004961:Estramustine; D005485:Flutamide; D003534:Cyproterone